Does Compounded Tirzepatide Work? Efficacy Evidence, Salt Forms, and What the Trials Actually Show

SURMOUNT-1 randomized 2,539 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo for 72 weeks. None of the participants had diabetes.

Results were striking. Mean weight reduction from baseline was 16.0% with 5 mg, 21.4% with 10 mg, and 22.5% with 15 mg, compared to 3.1% with placebo. More than one-third of participants receiving the 15 mg dose lost 25% or more of their body weight. No anti-obesity medication had previously achieved these numbers in a controlled trial (Jastreboff et al., NEJM, 2022).

These figures represent what happens when a patient receives verified-potency, cGMP-manufactured tirzepatide base in a controlled clinical setting. They do not represent what happens with a compounded product from an unknown pharmacy using an untested salt form. The difference is not academic. It is the difference between a guaranteed 22% weight loss and a hope that the product works similarly. For a full profile of the molecule, visit our tirzepatide overview.

SURMOUNT-3 tested tirzepatide in participants who had already lost at least 5% body weight through intensive lifestyle intervention. The tirzepatide group lost an additional 18.4% of body weight over 72 weeks, compared to a 2.5% gain in the placebo group. This demonstrated that tirzepatide produces results beyond what diet and exercise alone can achieve (Wadden et al., Nature Medicine, 2023).

SURMOUNT-4 addressed durability. After 36 weeks of open-label tirzepatide treatment (mean weight reduction of 20.9%), participants were randomized to continue tirzepatide or switch to placebo for an additional 52 weeks. Those who continued lost an additional 5.5%, reaching a total reduction of 25.3% at 88 weeks. Those switched to placebo regained weight, ending at 9.9% total reduction (Aronne et al., JAMA, 2024).

The takeaway for compounded users: tirzepatide works when the drug is consistently potent and consistently administered. Any interruption in potency, whether from a sub-potent batch, degraded product, or inconsistent salt form, can trigger the same rebound seen in the placebo arm of SURMOUNT-4.

The most recent trial, SURMOUNT-5, directly compared tirzepatide 15 mg to semaglutide 2.4 mg (Wegovy) in adults with obesity. At 72 weeks, tirzepatide produced superior weight reduction and greater waist circumference decrease compared to semaglutide (Lilly Investor Relations, 2024). This head-to-head result reinforced tirzepatide's position as the most effective GLP-1-class medication currently available.

However, both arms used manufacturer-produced, FDA-approved products. Neither arm used compounded versions of either drug. The superiority of tirzepatide over semaglutide has been demonstrated only with brand-name formulations. For patients comparing weight loss options, see our best peptides for weight loss guide.

Tirzepatide base has a molecular weight of 4,813.45 Da. It is the uncharged, unmodified peptide molecule. All pharmacokinetic parameters published in the FDA approval package, including absorption rate, bioavailability, half-life (approximately 5 days), and receptor binding affinity, were measured using this form.

When a compounding pharmacy uses tirzepatide base as its starting material, the active ingredient is chemically identical to what Eli Lilly puts in Mounjaro pens. The remaining variables are potency (did the pharmacy get the concentration right?), sterility (is the solution free of contaminants?), and stability (will the molecule remain intact through the beyond-use date?). These are serious variables, but the molecule itself is not a question mark.

For patients preparing compounded tirzepatide from vials, our how to reconstitute tirzepatide guide covers proper technique. Use the peptide reconstitution calculator to verify dilution volumes.

Tirzepatide acetate is a salt form where the peptide molecule is combined with acetic acid as a counterion. Many compounding pharmacies source tirzepatide acetate from raw material suppliers because it is more stable as a powder, easier to handle, and often cheaper than the free base form.

The problem: no clinical trial has tested tirzepatide acetate for efficacy or safety in humans. Salt form changes in peptide drugs can alter solubility, pH in solution, absorption kinetics, and injection site tolerability. For many small-molecule drugs, salt form differences are well-characterized and clinically irrelevant. For large peptides like tirzepatide (39 amino acids), the impact is less predictable (FDA Guidance on Compounding, 2023).

This does not mean tirzepatide acetate is ineffective. The tirzepatide molecule itself is likely intact and bioactive. But "likely" is not the same as "proven." The acetate counterion may change the pH of the reconstituted solution, which could affect subcutaneous absorption rates. It may alter the stability profile, leading to faster degradation in the vial. It may irritate injection sites differently than the base form. Without published pharmacokinetic studies comparing acetate to base, patients are relying on theoretical reasoning rather than clinical evidence.

Tirzepatide sodium salt (CAS 2023788-19-2) is another common compounding starting material. The FDA has specifically flagged the use of tirzepatide salts as a safety concern, noting that compounded products using salt forms are not copies of the approved drug and may have different pharmacological properties (FDA Safety Communication, 2024).

The sodium counterion adds molecular weight and can change the molecule's behavior in solution. Different pH, different osmolality, potentially different absorption. A sodium salt of tirzepatide is not the same chemical entity as tirzepatide base, even though the active peptide sequence is identical. The FDA considers this distinction important enough to have issued public warnings about it.

For patients evaluating compounded products, the salt form used is one of the first questions to ask the pharmacy. If they cannot tell you whether they use base, acetate, or sodium, or if they do not understand why it matters, that is a red flag about their overall quality standards.

A reputable compounding pharmacy will test each batch of tirzepatide for potency using an HPLC assay or equivalent validated method. The result should show that the actual concentration falls within 90-110% of the labeled concentration, the standard range for injectable drugs. The pharmacy should be able to provide a Certificate of Analysis (CoA) for each batch, showing the test date, method, result, and the identity of the testing laboratory.

503B outsourcing facilities are required to conduct potency testing on every batch before release. This is a federal requirement under cGMP rules. 503A pharmacies, which operate under state regulation, may or may not test each batch, depending on state law and the pharmacy's internal policies. Some 503A pharmacies send samples to third-party labs. Others rely on the potency certificate from their raw material supplier, which tests the powder before compounding but not the final product after reconstitution.

The difference matters. A raw material CoA confirms that the tirzepatide powder is potent. It does not confirm that the pharmacy measured it correctly, dissolved it properly, maintained sterility, or stored it at the right temperature. Final product testing is the only way to verify what the patient actually receives. To plan your dosing protocol around verified potency, use our tirzepatide dosage calculator.

In 2023, the FDA tested samples from multiple compounding pharmacies producing GLP-1 receptor agonists including tirzepatide. The results were alarming: 28% of tested sterile compounded preparations failed quality standards. Failures included sub-potent active ingredients (less drug than labeled), super-potent batches (more drug than labeled, increasing side effect risk), contamination with particulate matter, and incorrect pH values (FDA Compounding Survey, 2023).

Sub-potent tirzepatide means less weight loss, or no weight loss at all. A vial labeled as 10 mg/mL that actually contains 6 mg/mL will not produce SURMOUNT-level results, no matter how faithfully the patient follows the dosing schedule. The patient concludes that "compounded tirzepatide does not work" when the real problem is that they received 60% of the intended dose.

Super-potent batches carry the opposite risk. A patient titrating carefully from 2.5 mg to 5 mg who unknowingly receives a 7 mg dose may experience severe nausea, vomiting, or pancreatitis. The tirzepatide dosage chart in units assumes accurate potency. Inaccurate potency makes the entire dosing protocol unreliable.

Before filling a compounded tirzepatide prescription, ask the pharmacy these questions:

1. 1.Do you test each batch for potency before dispensing? The only acceptable answer is yes.
2. 2.What method do you use for potency testing? HPLC or a validated equivalent is the standard.
3. 3.Can you provide a Certificate of Analysis for my specific batch? If they cannot, the product was not tested.
4. 4.Is your testing done in-house or by a third-party laboratory? Third-party testing from an ISO-accredited lab is more reliable than in-house testing.
5. 5.What is your acceptance range for potency? 90-110% of label claim is the industry standard for injectables.

If the pharmacy cannot answer these questions clearly, or if they become defensive, source your prescription elsewhere. The cost savings of compounded tirzepatide mean nothing if the product does not contain the right amount of drug. For cost comparisons between compounded and brand-name options, see our tirzepatide cost with insurance breakdown and use the peptide cost calculator.

Patients receiving compounded tirzepatide from PCAB-accredited 503B outsourcing facilities frequently report weight loss trajectories consistent with SURMOUNT trial data. Weight loss of 10-15% over 12-16 weeks at maintenance doses of 10-15 mg per week is commonly reported in online patient communities and telehealth provider testimonials.

These outcomes make pharmacological sense. If the compounded product uses tirzepatide base at correct potency, the molecule binds the same GIP and GLP-1 receptors, activates the same intracellular signaling cascades, and produces the same appetite suppression, delayed gastric emptying, and improved insulin sensitivity. The chemistry does not care whether the vial has a Lilly logo or a compounding pharmacy label.

Several obesity medicine physicians have reported in conference presentations and medical forums that their patients on compounded tirzepatide from reputable 503B pharmacies show comparable weight loss, HbA1c reduction, and metabolic improvement to those on brand-name Mounjaro. These clinical observations, while not peer-reviewed data, are consistent with the expected pharmacology. For expected timelines, see our guide on how long tirzepatide takes to work.

Not all reports are positive. Common complaints about compounded tirzepatide include:

No weight loss or minimal weight loss. The most likely explanation is sub-potent product. If the vial contains less tirzepatide than labeled, the patient receives a lower effective dose. A patient who thinks they are taking 10 mg but is actually receiving 5 mg will lose weight more slowly, if at all.

Excessive side effects at low doses. Severe nausea, persistent vomiting, or diarrhea at starting doses (2.5 mg) can indicate a super-potent batch. Brand-name tirzepatide at 2.5 mg typically causes mild nausea in 12-18% of patients. If a compounded 2.5 mg dose causes severe GI distress, the actual dose may be higher. Review tirzepatide before and after results to understand expected side effect patterns.

Injection site reactions disproportionate to dose. Excessive redness, swelling, or pain at the injection site may indicate incorrect pH, improper buffering, or contamination in the compounded solution rather than a reaction to tirzepatide itself.

Product appearance changes. Cloudiness, particulate matter, color changes, or unusual viscosity in the vial indicate potential degradation, contamination, or formulation errors. Brand-name Mounjaro is a clear, colorless to slightly yellow solution. Any compounded product that looks different should not be injected.

If you experience unexpected results at any point, consult your prescriber. For help with proper injection technique, see where to buy tirzepatide for sourcing guidance and review the full tirzepatide profile.

When the FDA placed tirzepatide on its Drug Shortage List in December 2022, it activated a legal pathway under federal law that allows compounding pharmacies to produce copies of commercially available drugs during confirmed shortages. Demand for Mounjaro had outstripped Eli Lilly's manufacturing capacity within months of the drug's June 2022 launch.

This shortage exemption led to explosive growth in compounded tirzepatide. Hundreds of pharmacies began producing the peptide. Telehealth platforms built entire business models around prescribing compounded GLP-1 agonists at a fraction of brand-name cost. By mid-2024, an estimated 50,000 to 100,000 patients were receiving compounded tirzepatide monthly.

Eli Lilly invested over $5 billion in new manufacturing facilities. By late 2024, the FDA determined that the tirzepatide shortage had been resolved. This resolution ended the legal basis for most compounding under the shortage exemption. For a broader view of how this affects peptide access, see our FDA peptide crackdown 2026 analysis.

The end of the shortage exemption triggered immediate legal challenges. Multiple compounding pharmacies and industry organizations filed lawsuits against the FDA, arguing that the shortage resolution was premature and that patients would lose access to affordable medication.

Several courts issued temporary restraining orders allowing continued compounding during litigation. As of April 2026, the legal landscape remains fragmented. Some 503A pharmacies continue to compound tirzepatide under patient-specific prescriptions, arguing that the right to compound is independent of shortage status when a physician determines medical necessity. Many 503B outsourcing facilities have scaled back or ceased tirzepatide production due to increased FDA scrutiny.

The practical effect for patients: compounded tirzepatide is harder to obtain in 2026 than it was in 2023-2024. Pharmacies that continue to produce it face uncertain legal footing. Some have shifted to tirzepatide salt forms (acetate, sodium) rather than copies of the exact base form, arguing that salt forms are different chemical entities not subject to the same compounding restrictions. This legal argument is contested, and it introduces the potency and bioequivalence concerns discussed earlier.

If you are currently using compounded tirzepatide or considering it, here is the regulatory reality:

503B outsourcing facilities that continue to produce tirzepatide do so under increasing FDA scrutiny. Some have received warning letters. Others operate under court orders allowing continued production during litigation. The quality of product from these facilities may be affected by the uncertainty, as some have reduced quality control investment or shifted to cheaper salt form starting materials.

503A pharmacies may still compound tirzepatide with a valid patient-specific prescription from a licensed prescriber who documents medical necessity. The legal basis is strongest when the prescriber can demonstrate that the patient has a legitimate clinical need that brand-name products cannot meet, such as an allergy to an inactive ingredient in Mounjaro.

Online and international sources operate entirely outside the US regulatory framework. Products from these sources carry the highest risk of sub-potency, contamination, and counterfeit ingredients. The FDA has seized shipments of unapproved tirzepatide at the border and issued import alerts.

Regardless of the source, anyone using compounded tirzepatide should track their results carefully. Weight loss of 3-5% per month during the titration phase (first 16-20 weeks) is consistent with the SURMOUNT data. If you are not seeing results on compounded product, the molecule may not be the problem. The product may be. For more details on sourcing, see where to buy tirzepatide.

The Pharmacy Compounding Accreditation Board (PCAB) provides voluntary accreditation for compounding pharmacies that meet rigorous quality standards, including environmental monitoring, personnel competency, potency and sterility testing, and documented standard operating procedures. PCAB accreditation does not guarantee perfection, but it represents the highest quality tier available for compounded products.

A PCAB-accredited 503B facility is the closest you can get to pharmaceutical-grade manufacturing outside of a drug company. These facilities undergo regular inspections, maintain detailed batch records, and test every lot before release. If your pharmacy is not PCAB-accredited, ask why.

Ask your pharmacy whether they use tirzepatide base, tirzepatide acetate, or tirzepatide sodium. If they use a salt form, ask for the rationale and any bioequivalence data they rely on. The strongest evidence supports tirzepatide base, as it is the form tested in all SURMOUNT trials.

Some pharmacies may use acetate or sodium because the base form is harder to source or more expensive. That is a business decision, not a clinical one. If your pharmacy uses a salt form, you should understand that you are injecting a chemical entity that has never been tested in a published clinical trial. The risk may be low. It is not zero.

Weigh yourself at the same time each week, under the same conditions. Track your food intake. Note side effects. Compare your trajectory to the SURMOUNT data.

Expected weight loss on properly dosed tirzepatide: - Weeks 1-4 (2.5 mg): 1-3% body weight loss - Weeks 5-8 (5 mg): Additional 2-4% loss - Weeks 9-12 (7.5 mg): Additional 2-3% loss - Weeks 13-20 (10-15 mg): Additional 3-6% loss - Total at 20 weeks: 8-16% body weight loss

If your results fall significantly below these benchmarks despite adherence to dosing and dietary recommendations, the product potency is suspect. Discuss switching to brand-name product or a different pharmacy with your prescriber. For detailed titration protocols, review the compound tirzepatide dosage chart and the tirzepatide dosage chart in units.

Compounded tirzepatide in multi-dose vials is more sensitive to storage conditions than brand-name pre-filled pens. Improper handling can degrade the peptide, reducing potency even if the pharmacy produced it correctly.

Storage rules: - Refrigerate at 2-8 degrees Celsius (36-46 degrees Fahrenheit) at all times after receiving - Never freeze tirzepatide - Protect from light (keep in original packaging or wrap vial in foil) - Use within the beyond-use date assigned by the pharmacy (typically 28-42 days after compounding) - Do not use if the solution appears cloudy, discolored, or contains particles - After reconstitution (if applicable), keep refrigerated and use within 28 days

For step-by-step preparation instructions, see our how to reconstitute tirzepatide guide. Our peptide reconstitution calculator will help you calculate exact volumes for your prescribed dose.